Figure 6.
(A) SDS–PAGE analysis of co-expressed INTS3–hNABP1–C9ORF80 (left) and INTS3–hNABP2–C9ORF80 (right) complex purified with Glutathione sepharose followed by Ni-NTA chromatography. (B) Western blot analysis for the purified INTS3–hNABP1–C9ORF80 (left) and INTS3–hNABP2–C9ORF80 (right) complex using respective antibodies. (C) Representative EMSA images of INTS3–hNABP1–C9ORF80 complex binding with dT30 (left), rU30 (middle), and their quantitative analysis (right). (D) Representative EMSA images of INTS3–hNABP2–C9ORF80 complex binding with dT30 (left), rU30 (middle), and their quantitative analysis (right).
Purification and binding ability of INTS3–hNABP1/2–C9ORF80 heterotrimeric complex.

(A) SDS–PAGE analysis of co-expressed INTS3–hNABP1–C9ORF80 (left) and INTS3–hNABP2–C9ORF80 (right) complex purified with Glutathione sepharose followed by Ni-NTA chromatography. (B) Western blot analysis for the purified INTS3–hNABP1–C9ORF80 (left) and INTS3–hNABP2–C9ORF80 (right) complex using respective antibodies. (C) Representative EMSA images of INTS3–hNABP1–C9ORF80 complex binding with dT30 (left), rU30 (middle), and their quantitative analysis (right). (D) Representative EMSA images of INTS3–hNABP2–C9ORF80 complex binding with dT30 (left), rU30 (middle), and their quantitative analysis (right).

Close Modal

or Create an Account

Close Modal
Close Modal